Navigation Links
WellPoint Reports First Quarter 2009 Results
Date:4/22/2009

ype Local Group (3.4%) (3.7%) National Accounts 4.7% 4.3% BlueCard 2.1% 2.3% Total National 3.6% 3.5% Individual (1.6%) (5.6%) Senior (3.7%) (3.5%) State Sponsored (12.6%) (19.3%) FEP (0.6%) (0.1%) Total Medical Membership (1.4%) (2.3%) Funding Arrangement Self-Funded 0.7% 1.6% Fully-Insured (3.7%) (6.5%) Total Medical Membership (1.4%) (2.3%) Reportable Segment Commercial (0.6%) (1.0%) Consumer (6.0%) (9.6%) Other (0.6%) (0.1%) Total Medical Membership (1.4%) (2.3%) Other Membership ---------------- Behavioral Health Membership (0.2%) 0.7% Life and Disability Membership (0.1%) (2.2%) Dental Membership (4.1%) (9.0%) Vision Membership 6.4% 9.4% Medicare Part D Membership (8.8%) (7.1%) PBM Prescription Volume Paid (Quarterly) ---------------- Retail Scripts (2.4%) (3.8%) Mail Order Scripts (3.3%) (5.0%) Specialty Pharmacy Scripts 0.5% 37.0% Total Scripts (2.5%) (3.8%) WellPoint, Inc. Consolidated Statements of Income (Unaudited) Three Months Ended
'/>"/>
SOURCE WellPoint, Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion
2. Charles Kennedy, M.D., Vice President for Health Information Technology, WellPoint, Inc., Appointed to National Health I.T. Policy Committee
3. AMA Announces Physician Class Action Against WellPoint
4. WellPoint Announces Strategic Relationship With Availity to Enhance the Provider and Health Plan Relationship and Advance Improvements in Patient Care
5. WellPoint Named to DiversityIncs 2009 DiversityInc Top 50 Companies for Diversity(R)
6. WellPoint Announces Appearances at Upcoming Conferences
7. WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program
8. WellPoint Highlights Operational Accomplishments and Details 2009 Guidance at Annual Investor Meeting
9. WellPoint Announces Appearance at 2nd Annual Medicaid Managed Care Summit
10. National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
11. WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... as ski resorts,are opening for the season, the Kelly Brush ... Campaign with the announcement of,over $20,000 in grants to ski ... of a campaign to promote and improve ski racing safety. ... are some of the most prestigious racing programs in,the nation ...
... Respond to Infectious Disease Epidemics in Africa , ... formerly the Academic Alliance Foundation, has received a $12.5 ... to support a landmark study to identify the most ... sub-Saharan Africa to treat infectious diseases such as HIV/AIDS, ...
... E6 Ventures has agreed to,participate in the next ... up,in 2005 by its chief technical officer, Sergey Aleksandrov, ... developed a low temperature,process to create thick amorphous diamond-like ... in a number of industrial sectors. , ...
... are feeling,financially, emotionally and physically stressed. Your fuse is ... seems the farthest thing,from your mind. In a world ... we remain connected 24/7, yet alone. Is it possible ... new ,old, trend?,Join the One Spirit(R) Book Club and ...
... A new study found that adolescents were at the greatest ... early age and the parents, smoking quickly reached high levels ... the November issue of Health Psychology , draws from ... research that suggests smoking behavior is influenced by both genetics ...
... Bavituximab, an anti-viral drug developed by UT Southwestern Medical ... fight viral diseases, including potential bioterrorism agents. , ... Nature Medicine , groups of guinea pigs infected ... from the fatal disease when treated with bavituximab alone ...
Other Medicine News:Health News:Kelly Brush Foundation Awards Ski Racing Safety Grants 2Health News:Accordia Global Health Foundation Receives $12.5 Million Grant From Bill & Melinda Gates Foundation 2Health News:E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd 2Health News:E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd 3Health News:Engaging In Life with One Spirit Book Club 2Health News:Smoking, teens and their parents: New research 2Health News:UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs 2
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... BERKELEY, Calif., Oct. 7 Aerovance Inc. today ... I trial of its Aerovant,inhalation powder that demonstrate ... asthma patients, inhalation of a single 10 mg,dose., ... highest of three doses investigated in,Aerovance,s Phase IIb ...
... Planned 15 Patient Cohort Enrolled in Stage A of ... Combination With Carboplatin and Paclitaxel -, TUSTIN, Calif., ... a clinical stage biopharmaceutical,company developing monoclonal antibodies for the ... announced that it has completed,enrollment in the first stage ...
Other Medicine Technology:Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4
Inquire...
Inquire...
Quick Release Holder for the 8000 Series Sliding Microtome. A simple to use hlder for wax cassettes. Accepts standard size wax cassettes (26 x 31 x 5mm). Can be specified instead of standard vice ...
Quick Release Holder designed for the 8000 Series Microtome to hold hardboard squares....
Medicine Products: